Anesthesiologie, chronische pijn central sensibilisation Chronic pain
Conditions
Interventions
For tapentadol we will start titrating with 50mg 2x/day and increase the dose
by 50mg 2x/day every 3 days until sufficient analgesia is reached with
tolerable adverse effects. The maximum recommende
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Gender: female 2. Age: 18 years and older 3. Presence of proven endometriosis or CLBPr 4. Signs of central sensitization 5. No contraindications for opioids or pregabalin. 6. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. No or insufficient understanding of Dutch language. 2. Incapacity to follow instructions. 3. Mental incompetence to provide informed consent. 4. CLBP with radiation to both legs. 5. Pain in one (or more) sites where QST will be applied. 6. Usage of opioids with more powerful spectre, such as oxycodone, fentanyl, morphine in the week prior to start of the study. 7. Previous usage of pregabalin or tapentadol 8. Alcohol abuse. 9. Pregnancy or woman who wish to be pregnant. 10. Kidney and/or liver function disturbances in patients with a medical history (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Central Sensitisation parameters • pressure pain threshold (PPT) • pressure pain tolerance threshold (PTT) • conditioned pain modulation (CPM) • size of allodynia • Wind-up ratio • CSI | — |
Secondary
| Measure | Time frame |
|---|---|
| • NRS • PDI • PCS • PVAQ • Adverse effects of the medications • Dosages of the medication during the treatment period | — |
Countries
Netherlands
Outcome results
None listed